BioPharmSignal logoBioPharmSignal

Biotech News

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

MannKind (MNKD)MannKindEarnings

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, announced today

Related news

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MNKDMannKind2026-05-06 20:01 EST

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

ALTAltimmune2026-05-06 11:30 EST

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

LXRXLexicon Pharmaceuticals2026-04-30 12:00 EST

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

CVRXCVRx2026-04-27 20:30 EST

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

RYTMRhythm Pharmaceuticals2026-04-09 12:00 EST

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

BLTEBelite Bio2026-05-13 20:00 EST

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

MLYSMineralys Therapeutics2026-04-29 20:05 EST

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

VKTXViking Therapeutics2026-04-22 20:35 EST

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

View all latest news

MannKind

Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...

Recent company news

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MNKDMannKind2026-07-29 10:30 EST

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MNKDMannKind2026-07-24 10:35 EST

MannKind Announces $50 Million Private Placement

MNKDMannKind2026-07-24 10:30 EST

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

Stock data

Close
3.89 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States